氯噻酮(Chlorthalidone) - 药物靶点：NCC_在研适应症：尿崩症，水肿，肾石病_专利_临床

概要

基本信息

简介氯噻酮是一种小分子药物，通过抑制负责肾脏中钠和氯化物重吸收的NCC蛋白起作用。这种药物是治疗尿崩症、高血压、肾结石和水肿的有用工具。赛诺菲是一家制药公司，于1959年率先开发并获得氯噻酮使用批准。作为一种利尿药物，氯噻酮通常用于通过增加尿液量和减少体内液体量来控制高血压。它在治疗一系列疾病方面的有效性，加上其悠久的历史，使其成为医疗领域的一种有价值的药物。

药物类型

小分子化药

别名

1-keto-3-(3'-sulfamyl-4'-chlorophenyl)-3-hydroxyisoindoline、1-oxo-3-(3-sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline、2-chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide

+ [16]

靶点

NCC

作用机制

NCC抑制剂(噻嗪类敏感氯化钠协同转运蛋白抑制剂)

治疗领域

神经系统疾病心血管疾病内分泌与代谢疾病+ [2]

在研适应症

尿崩症水肿肾石病+ [1]

非在研适应症-

原研机构

在研机构

非在研机构

Sanofi-Aventis U.S. LLC

最高研发阶段批准上市

首次获批日期

瑞士 (1959-01-01),

高血压

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构

分子式C14H11ClN2O4S

InChIKeyJIVPVXMEBJLZRO-UHFFFAOYSA-N

CAS号77-36-1

关联

67

项与氯噻酮相关的临床试验

NCT02493322 / Not yet recruiting临床3期

Efficacy and Safety Evaluation of the New Association on Fixed Dose of Olmesartan + Chlorthalidone, Produced by EMS S.A,in Arterial Hypertension Control

The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.

开始日期2024-12-01

申办/合作机构

EMS SA (Brazil)

NCT02483936 / Not yet recruiting临床3期

Efficacy and Safety Evaluation of the New Association on Fixed Dose of Olmesartan Medoxomil + Chlorthalidone (40mg + 12.5mg and 40mg + 25mg) Compared With BENICAR HCT® in Hypertension Control

The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.

开始日期2024-12-01

申办/合作机构

EMS SA (Brazil)

NCT06111885 / Recruiting临床2期

Randomized, Double-blind, Crossover Trial Assessing the Efficacy of Indapamide and Chlorthalidone Compared to Hydrochlorothiazide for the Reduction of Urine Supersaturation for Kidney Stone Prevention

The aim of this study is to test the efficacy of the two long-acting thiazide-like diuretics indapamide and chlorthalidone in reducing urine supersaturation for calcium oxalate and calcium phosphate compared to the short-acting thiazide diuretic hydrochlorothiazide for the prevention of calcium-containing kidney stones.

开始日期2024-10-01

申办/合作机构

Insel Gruppe AG

[+1]

100 项与氯噻酮相关的临床结果

登录后查看更多信息

100 项与氯噻酮相关的转化医学

登录后查看更多信息

100 项与氯噻酮相关的专利（医药）

登录后查看更多信息

1,655

项与氯噻酮相关的文献（医药）

2024-11-01·JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION

Probable chlorthalidone-induced hypokalemic rhabdomyolysis

Article

作者: Canton, Caitlin ; Singh, Gagandeep ; Langworthy, Diana

OBJECTIVE:

A case of hypokalemic rhabdomyolysis related to chlorthalidone use is reported SUMMARY: A 52-year-old male was admitted to the hospital for acute onset generalized weakness and was found to have severe hypokalemia and rhabdomyolysis. The patient had been on chlorthalidone therapy with a dose increase from 25mg daily to 50mg daily two months prior to admission. Extensive workup ruled out neurologic, rheumatologic and endocrinologic causes of hypokalemia. In the absence of other causes, it was determined that the patient was experiencing a severe presentation of chlorthalidone-induced hypokalemia resulting in rhabdomyolysis. The patient's rhabdomyolysis and weakness improved with aggressive potassium correction, and potassium wasting eventually resolved with discontinuation of chlorthalidone.

CONCLUSION:

Although mild hypokalemia is a known side effect of thiazide and thiazide-like diuretics, health care providers should be aware of the possibility of severe manifestations of this adverse reaction, even at relatively small dose increases.

2024-11-01·AMERICAN JOURNAL OF CARDIOLOGY

Prevention of Heart Failure in Hypertension—the Role of Coronary Heart Disease Events Treated With Versus Without Revascularization: The ALLHAT Study

Article

作者: Davis, Barry R ; Kapadia, Samir R. ; Kattan, Michael W ; Kattan, Michael W. ; Kapadia, Samir R ; Chen, Vincent ; Tereshchenko, Larisa G ; Davis, Barry R. ; Tereshchenko, Larisa G.

In modern clinical practice, less than half of patients with new-onset heart failure (HF) undergo ischemic evaluation and only a minority undergo revascularization. We aimed to assess the proportion of the effect of hypertension (antihypertensive treatment) on incident HF to be eliminated by prevention of coronary heart disease (CHD) event treated with or without revascularization, considering possible treatment-mediator interaction. The causal mediation analysis of Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) included 42,418 participants (age 66.9 ± 7.7, 35.6% black, 53.2% men). A new CHD event (myocardial infarction or angina) that occurred after randomization but before the incident HF outcome was the mediator. Incident symptomatic congestive HF (CHF) and hospitalized/fatal HF (HHF) were the primary and secondary outcomes, respectively. Logistic regression (for mediator) and Cox proportional hazards regression (for outcome) were adjusted for demographics, cardiovascular disease history, and risk factors. During a median 4.5-year follow-up, 2,785 patients developed CHF, including 2,216 HHF events. Participants who developed CHD events had twice the higher incidence rate of CHF than CHD-free (28.5 vs 13.9 events/1,000 person-years). The proportion of reference interaction indicating direct harm because of a CHD event for lisinopril (234% for CHF, 355% for HHF) and amlodipine (244% for CHF, 468% for HHF) was greater than for chlortalidone (143% for CHF, 269% for HHF). In patients with revascularized CHD events, chlortalidone and amlodipine eliminated 21% to 24% and lisinopril eliminated -45% of HHF. Antihypertensive treatment could not eliminate harm from CHD events treated without revascularization. In conclusion, the antihypertensive drugs (chlortalidone, lisinopril, and amlodipine) prevent HF not principally by preventing CHD events but by way of other pathways. HF is moderated but not mediated by CHD events. Revascularization of CHD events is paramount for HF prevention.

2024-11-01·Drug testing and analysis

Elimination profile of low‐dose chlortalidone and its detection in hair for doping analysis—Implication for unintentional non‐therapeutic exposure

Article

作者: Anielski, Patricia ; Weigel, Kai ; Sporkert, Frank ; Keiler, Annekathrin M. ; Krumbholz, Aniko ; Thieme, Detlef

Abstract:

Chlortalidone (CLT) is a thiazide‐type diuretic with high affinity for the erythrocyte carbonic anhydrase. Therapeutically, it is mostly used to treat edema and hypertension due to liver cirrhosis, heart insufficiency, or renal dysfunction. Although diuretics and masking agents are prohibited by the World Anti‐Doping Agency (WADA) at all times in sports, substances belonging to this category are constantly detected in athlete samples, according to WADA's annual testing figures. Within this group of structurally diverse compounds, a threshold of 20 ng/mL has been introduced for six substances solely due to their presence as contaminants in other permitted drugs because of pharmaceutical production processes. In a recent presumptive doping case with a low urinary CLT concentration, the question of unintentional doping, for example, by contaminated non‐steroidal anti‐inflammatory drug intake, arose. To examine this potential scenario, a co‐elimination of low‐dose CLT and hydrochlorothiazide (HCTA; 20 × 50 μg, 0.2 mg/day each) was conducted on five consecutive days in two volunteers. Urine samples were subjected to liquid chromatography‐tandem mass spectrometry (LC–MS/MS). Moreover, we examined the incorporation of CLT in scalp hair. HCTA is rapidly excreted renally in comparatively high concentrations. In contrast, the elimination of CLT is considerably slower (terminal elimination half‐life extended by a factor of 12) and, consequently, much less concentrated in corresponding urine samples (45 and 53 ng/mL, respectively). Conversely, a higher hair incorporation of chlorthalidone was observed with simultaneous dosing of both. The results suggest that an unintentional intake of sub‐therapeutic CLT doses due to contamination might result in an adverse analytical finding.

7

项与氯噻酮相关的新闻（医药）

2024-05-16

·PRNewswire

New Analysis on Hypertension Treatment to be Presented as Late-Breaking Research at National Kidney Foundation Spring Clinical Meetings

LONG BEACH, Calif., May 16, 2024 /PRNewswire/ -- A new analysis of a study comparing two commonly used medications, chlorthalidone (CTD) and hydrochlorothiazide (HCTZ), is set to be presented as a late-breaking presentation at the annual 2024 National Kidney Foundation Spring Clinical Meetings. Continue Reading The study, titled "Treatment with Chlorthalidone vs Hydrochlorothiazide and Renal Outcomes: The Diuretic Comparison Project (DCP)," conducted by a team of distinguished researchers from various institutions and led by Areef Ishani, MD MS, Minneapolis VA Health Care System Primary Care and Specialty Care Integrated Care Community (ICC) Director and Professor of Medicine, University of Minnesota provides crucial insights into the impact of these medications on renal health in hypertensive patients. New study comparing two commonly used medications set to be shared as a late-breaking presentation at NKF's Conference. Post this Hypertension, or high blood pressure, is a significant risk factor for the development and progression of chronic kidney disease (CKD). Previous research had hinted at potential differences in kidney outcomes between chlorthalidone and hydrochlorothiazide. This new study followed more than 12,000 participants for an average of 3.9 years. The study found no significant disparity in renal outcomes between patients treated with chlorthalidone and those treated with hydrochlorothiazide. Specifically, there was no marked difference observed in the primary composite renal outcome, including doubling of serum creatinine, a significant drop in estimated glomerular filtration rate (eGFR), or kidney failure requiring treatment (KFRT), between the two treatment groups. Furthermore, the study revealed that the total slope of eGFR change and the incidence of chronic kidney disease (CKD) were comparable between patients receiving chlorthalidone and hydrochlorothiazide, suggesting similar efficacy in preserving kidney function. The findings offer reassurance that both chlorthalidone and hydrochlorothiazide may be equally effective choices for managing hypertension without compromising renal health. About NKF Spring Clinical Meetings For the past 32 years, nephrology healthcare professionals from across the country have come to NKF's Spring Clinical Meetings to learn about the newest developments related to all aspects of nephrology practice; network with colleagues; and present their research findings. The NKF Spring Clinical Meetings is designed for meaningful change in the multidisciplinary healthcare teams' skills, performance, and patient health outcomes. It is the only conference of its kind that focuses on translating science into practice for the entire healthcare team. About Kidney Disease In the United States, more than 37 million adults are estimated to have kidney disease, also known as chronic kidney disease (CKD)—and approximately 90 percent don't know they have it. About 1 in 3 adults in the U.S. are at risk for kidney disease. Risk factors for kidney disease include: diabetes, high blood pressure, heart disease, obesity, and family history. People of Black or African American, Hispanic or Latino, American Indian or Alaska Native, Asian American, or Native Hawaiian or Other Pacific Islander descent are at increased risk for developing the disease. Black or African American people are about four times as likely as White people to have kidney failure. Hispanics experience kidney failure at about double the rate of White people. About NKF Professional Memberships Healthcare professionals can join NKF to receive access to tools and resources for both patients and professionals, discounts on professional education, and access to a network of thousands of individuals who treat patients with kidney disease. About the National Kidney Foundation The National Kidney Foundation is revolutionizing the fight to save lives by eliminating preventable kidney disease, accelerating innovation for the dignity of the patient experience, and dismantling structural inequities in kidney care, dialysis, and transplantation. NKF Website Instagram Facebook X SOURCE The National Kidney Foundation

临床研究

2022-12-15

·Science Daily

New study method finds two blood pressure drugs equally effective

A clinical trial found that two first-line treatments for high blood pressure were equally effective. A large VA clinical trial found that the blood pressure drug chlorthalidone (CTD) was not superior to hydrochlorothiazide (HCTZ) for the prevention of cardiovascular disease or non-cancer death. Both drugs are in a class of medications called thiazide diuretics, commonly known as water pills. They are used to help the body rid itself of excess fluid, which can lower blood pressure. The study was a first-of-its-kind pragmatic trial that was embedded in usual clinical care. As part of VA's clinical trials enterprise, it allowed participation from across the country with no additional staff. Also, all study procedures were done as part of routine clinical care. There was no additional burden placed on Veterans who participated in the study, including no extra visits. "Because of the number of Veterans VA cares for and our systemwide electronic medical record, we were able to embed this massive clinical trial within day-to-day care without any additional burden to the thousands of Veterans who volunteered for this study," said Rachel Ramoni, VA's chief research and development officer. "The result is important evidence of how these widely-used medications work in the real world." Current clinical guidelines say that CTD may be more effective than HCTZ to lower blood pressure, but this recommendation is unsupported by direct evidence. Both medications have been used for more than 50 years and each is considered a first-line treatment for hypertension. "In 2020, Medicare reported that approximately 1.5 million people were prescribed CTD compared to 11.5 million prescribed HCTZ, despite guideline recommendations," said principal investigator Dr. Areef Ishani, director of the Minneapolis VA Health Care System's Primary Care and Specialty Care Integrated Care Community. "This discrepancy between clinical guidelines and real-world usage is possibly related to the belief that CTD has a greater risk of adverse effects without clear evidence for differences in cardiovascular outcomes." The Diuretic Comparison Project (CSP 597) is a large pragmatic clinical trial that was conducted at 537 VA medical centers and community clinics in the U.S. The trial enrolled more than 4,000 providers and 13,500 Veterans with high blood pressure who were taking HCTZ at baseline. Study participants were randomized to stay on their current dose of HCTZ or take an equivalent dose of CTD. Ninety-five percent of study participants were taking a lower dose of HCTZ, so the main study comparison was 12.5 mg CTD to 25 mg HCTZ. The team found no difference between the two drugs, at these lower doses, for the prevention of cardiovascular disease or non-cancer death, which included heart attack, stroke, heart failure, or lack of blood flow requiring medical intervention. There was a slight increase in the risk for low potassium in the CTD group, which quickly resolved with potassium supplements. "We were able to compare two commonly prescribed generic drugs using a low-cost methodology," said Ishani. "This trial has shown that large, embedded trials are operationally feasible. They can be incorporated into the clinical workflow of providers by leveraging the electronic health record and other existing infrastructure." The study was funded by the VA Cooperative Studies Program. The study results were published online December 14, 2022, by the New England Journal of Medicine.

临床结果AHA会议临床研究

2022-07-24

·丁香园

医生给高血压患者开氢氯噻嗪被医学生投诉！究竟谁错了？

近期在丁香园论坛闲逛，看到了这样一个病例：针对上述病例中的患者是否应该处方「氢氯噻嗪」，站友们的观点基本一致：「氢氯噻嗪确实会影响血糖和血尿酸，但是并没有禁用于这些情况，医生很多时候都是在权衡利弊。就算出现了副作用，血糖和尿酸也有其他调整的办法。而一旦停药导致患者血压控制不佳，甚至出现夹层、脑出血等严重并发症，后果不堪设想」。当然，医生确实也存在问题，应该提前告知患者用药的潜在风险，并做好定期复查。那么，临床中真的遇到这种情况究竟该怎么办呢？今天就给大家理一理。利尿剂该不该用？难治性高血压定义为在改善生活方式的基础上，应用了合理可耐受的足量 3 种或 3 种以上降压药物（包括利尿剂）一个月以上血压仍未达标，或服用 4 种或 4 种以上降压药物血压才能有效控制，称为难治性高血压。美国心脏协会曾发表「难治性高血压诊断、评估和治疗」的声明指出：未应用利尿剂或利尿剂剂量不足是导致难治性高血压的原因之一，增加利尿剂剂量是控制难治性高血压的主要手段。足以见其重要性。该患除利尿剂（氢氯噻嗪），已应用 3 种降压药（ARB、CCB、β 受体阻滞剂），若均已应用至合理可耐受的足量，血压控制仍欠佳，确实应加用利尿剂。用于控制血压的利尿剂主要是噻嗪类利尿剂，分为噻嗪型利尿剂和噻嗪样利尿剂两种，前者包括氢氯噻嗪和苄氟噻嗪等，后者包括氯噻酮和吲达帕胺等。此类药物尤其适用于老年高血压、单纯收缩期高血压或伴心力衰竭患者，也是难治性高血压的基础药物之一。小剂量噻嗪类利尿剂（如氢氯噻嗪 6.25～25 mg）对代谢的影响较小，不增加新发糖尿病的风险。其与 ACEI/ARB 联用，具有协同降压作用，利尿剂的不良反应减少，从而降低糖尿病患者的病死率和心血管病发生率。RAAS 抑制剂联合低剂量利尿剂的固定复方制剂也推荐用于高血压伴糖尿病的治疗。大剂量噻嗪类利尿剂或与 β 受体阻滞剂联用可能对糖脂代谢或电解质平衡有影响，不建议大剂量应用或二者联用。若必须联用，应结合患者情况，做好定期复查。合并高尿酸血症的患者应慎用利尿剂。做好定期复查。难治性高血压的药物选择1）需要联合 ≥ 3 种不同降压机制的药物，应选择长效或固定复方制剂以减少给药次数和片数。酌情将全天用药一次或分成早、晚服用，以控制全天血压。2）三药联合方案推荐 RAS 抑制剂 + CCB + 噻嗪类利尿剂，药物剂量应为常规或双倍的可耐受剂量。对于血钾＜ 4.5 mmol/L、eGFR ＞ 45 mL/（min · 1.73m²）的患者可以考虑使用螺内酯作为第 4 种药物。3）对高肾素及高交感患者以 RAS 抑制剂和 β 受体阻滞剂治疗为主；对醛固酮增多症患者，应加用螺内酯；对容量增高及循环 RAS 低下患者，以 CCB 和利尿剂为主。4）对摄盐量大或盐敏感患者，在强调严格限盐的同时适当增加噻嗪类利尿剂用量；对 eGFR ≤ 30 mL/（min · 1.73m²）的患者应采用袢利尿剂。非透析的肾功能不全患者由于 RAS 抑制剂的使用或剂量受限，应增加 CCB 的剂量，甚至将二氢吡啶类与非二氢吡啶类 CCB 合用，必要时联合 β 受体阻滞剂、α、β 受体阻滞剂或 α 受体阻滞剂。血压仍不能达标时可以考虑使用可乐定、利血平等中枢神经抑制药物。5）ARNI 是一种同时作用于 RAAS 和 NPs、增强 NPs 的血压调节作用同时抑制 RAAS 而实现多途径降压的新型药物。沙库巴曲缬沙坦可用于原发性高血压患者的降压治疗，常规剂量为 200 mg，1 次/d，对于难治性高血压患者可增至 300～400 mg/d。高龄老年人、伴有 HFrEF 的患者、合并 CKD 3～4 期的患者可从低剂量 50～100 mg/d 开始。如患者耐受，每 2～4 周将剂量加倍，以达到患者最适宜的剂量，实现血压控制以及耐受的平衡。策划：ly投稿：wangliya1@dxy.cn题图：站酷海洛参考文献：[1] 孙宁玲, 霍勇, 王继光, 等. 难治性高血压诊断治疗中国专家共识 [J]. 中国介入心脏病血杂志,2013,21(2):69-73.[2] 国家卫生计生委合理用药专家委员会，中国医师协会高血压专业委员会. 高血压合理用药指南 (第 2 版)[J]. 中国医学前沿杂志 (电子版),2017,9(7):28-121.[3] 中国高血压防治指南修订委员会, 高血压联盟 (中国), 中华医学会心血管病学分会, 等. 中国高血压防治指南 (2018 年修订版)[J]. 中国心血管杂志,2019,24(1):24-55.[4] 中国医疗保健国际交流促进会高血压分会, 中国医师协会心血管分会, 中国高血压联盟, 等. 沙库巴曲缬沙坦在高血压患者临床应用的中国专家建议 [J]. 中华高血压杂志,2021,29(2):108-112.[5] Thomas Unger, Claudio Borghi, Fadi Charchar, et,al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines[J].J Hypertens,2020,38(6):982-1004.[6] 陈晓, 崔兆强, 林金秀, 等.2020 国际高血压学会全球高血压实践指南》解读 [J]. 中国医学前沿杂志 (电子版),2020,12(5):54-60.

100 项与氯噻酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00272	氯噻酮	C03BA04	DB00310

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
尿崩症	中国	成都第一制药有限公司	1985-01-01
水肿	中国	成都第一制药有限公司	1985-01-01
肾石病	中国	成都第一制药有限公司	1985-01-01
高血压	瑞士	Sanofi	1959-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02841280 (CLICK, Pubmed)	临床2期	慢性肾病 24-hour urinary sodium \| aldosterone \| plasma renin ... 更多	160	Chlorthalidone	繭淵繭願鏇鏇簾衊鹽繭(顧衊鑰餘選築鏇築膚鹽) = 觸構鑰鹽蓋齋鬱夢艱築憲鏇製鹽餘餘願窪網窪 (鏇製窪廠獵襯構憲網淵, 25.4 ~ 57.4) 更多	积极	2024-06-12
NCT02665117 (CTgov)	N/A	高血压	61	Potassium Magnesium Citrate (KMgCit)+chlorthalidone (KMgCit + Chlorthalidone)	襯顧選齋願顧襯廠淵壓(艱鏇鑰願膚艱糧艱簾糧) = 艱遞蓋遞積積餘廠餘鬱鑰網膚鹹鑰鏇顧淵蓋願 (遞鹹壓襯簾夢夢夢築觸, 鏇遞簾蓋衊顧廠蓋廠艱 ~ 網獵獵顧遞選繭糧顧壓) 更多	-	2023-10-25
				Potassium Chloride (KCl)+chlorthalidone (KCl + Chlorthalidone)	襯顧選齋願顧襯廠淵壓(艱鏇鑰願膚艱糧艱簾糧) = 鹽築餘積繭選築構製網鑰網膚鹹鑰鏇顧淵蓋願 (遞鹹壓襯簾夢夢夢築觸, 積範構窪壓壓齋醖廠壓 ~ 餘淵憲繭構鹽願範餘醖) 更多
NCT02841280 (CLICK, CTgov)	临床2期	高血压 \| 慢性肾病	160	Chlorthalidone (Chlorthalidone)	壓廠製夢餘膚淵廠範遞(壓艱糧憲壓顧築網糧襯) = 觸願淵觸簾網築鑰範獵範積觸醖構夢醖鬱蓋廠 (鏇獵憲襯鹹構襯憲鏇醖, 膚鹽選簾蓋願壓觸淵簾 ~ 製鬱築淵鹽艱鏇膚廠顧) 更多	-	2022-03-31
				Placebo (Placebo)	壓廠製夢餘膚淵廠範遞(壓艱糧憲壓顧築網糧襯) = 顧築憲衊選鹹積築鏇顧範積觸醖構夢醖鬱蓋廠 (鏇獵憲襯鹹構襯憲鏇醖, 糧構艱觸廠鑰鹽淵鬱範 ~ 構願範餘齋選艱糧鏇壓) 更多
NCT02841280 (Pubmed) 人工标引	临床2期	高血压 \| 慢性肾病	160	Chlorthalidone	積積膚廠襯構鹹餘鏇蓋(鑰構蓋壓製範觸窪壓醖) = 鹽選窪網淵繭鹹積鹹觸艱遞廠積膚繭鬱鑰艱夢 (壓廠蓋淵蓋簾鏇顧蓋廠, -13.9 ~ -8.1)	积极	2021-11-05
				Placebo	積積膚廠襯構鹹餘鏇蓋(鑰構蓋壓製範觸窪壓醖) = 憲鑰鏇鑰窪願鏇鬱廠廠艱遞廠積膚繭鬱鑰艱夢 (壓廠蓋淵蓋簾鏇顧蓋廠, -3.5 ~ 2.5)
NCT03325114 (CTgov)	临床2期	1型糖尿病 \| 高钙尿症	1	chlorthalidone	淵觸窪鏇積齋遞遞夢壓(願繭遞鏇淵淵觸積鑰簾) = 膚壓範夢鹽選網範蓋繭積構選膚餘壓構選襯夢 (鹹觸鹹繭鹽醖鬱遞鹹憲, 膚壓窪選醖衊憲糧夢願 ~ 簾鬱鹽壓壓蓋築鏇衊範) 更多	-	2021-01-05
HEBE Trial (ASN2020)	临床4期	慢性肾病	-	Bumetanide 2 mg BID + Chlorthalidone 50 mg BID	簾鏇餘衊廠窪鹽憲顧觸(顧淵願遞願廠糧鹽願觸) = 網壓壓網選簾淵願廠艱選簾齋夢壓鏇遞糧膚範 (願鬱顧蓋網願廠製蓋窪, 10.7) 更多	积极	2020-10-19
				Bumetanide 2 mg BID + Placebo	簾鏇餘衊廠窪鹽憲顧觸(顧淵願遞願廠糧鹽願觸) = 積餘壓簾衊糧願餘鑰遞選簾齋夢壓鏇遞糧膚範 (願鬱顧蓋網願廠製蓋窪, 11.9) 更多
NCT04393493 (CTgov)	临床2期	心肾综合征	80	Furosemide (Stepped Furosemide)	艱積餘齋積積簾窪襯鏇(窪鏇願窪膚壓鏇積艱鏇) = 廠範膚窪壓齋選夢艱艱積鹽餘網遞淵獵積膚蓋 (襯鬱夢醖衊窪餘淵鬱醖, 鏇鬱選顧鏇壓鏇壓淵鑰 ~ 鏇艱淵窪壓鹹積憲鏇範) 更多	-	2020-09-14
				Spironolactone+Furosemide+Chlortalidone (Diuretics Combined)	艱積餘齋積積簾窪襯鏇(窪鏇願窪膚壓鏇積艱鏇) = 構鏇膚鏇淵膚範衊衊積積鹽餘網遞淵獵積膚蓋 (襯鬱夢醖衊窪餘淵鬱醖, 鏇廠襯選衊衊構廠齋遞 ~ 構夢膚艱鑰窪淵艱簾憲) 更多
HEBE-CKD Trial (ESC2020)	N/A	慢性肾病	-	Bumetanide + Chlorthalidone	壓繭顧鏇鬱衊鹽艱壓淵(膚鏇艱壓襯夢餘齋製膚) = 憲構糧範築衊糧鏇齋鏇網獵觸艱膚廠餘獵繭鑰 (窪網顧構獵獵餘醖廠廠 ) 更多	积极	2020-08-30
				Bumetanide + Placebo	壓繭顧鏇鬱衊鹽艱壓淵(膚鏇艱壓襯夢餘齋製膚) = 醖餘憲淵積蓋繭簾積願網獵觸艱膚廠餘獵繭鑰 (窪網顧構獵獵餘醖廠廠 ) 更多
NCT03923933 (HEBE-CKD, CTgov)	临床2期	慢性肾病	34	Bumetanide (Placebo)	餘憲鬱夢淵獵繭衊範壓(願襯壓選網艱願觸膚鏇) = 齋餘願簾願鏇艱鑰夢廠夢鹹壓壓廠簾齋淵齋顧 (網鏇鑰顧糧襯選餘夢範, 醖糧選醖鹽壓觸餘襯鑰 ~ 網範餘淵獵夢壓衊糧繭) 更多	-	2020-03-10
				Bumetanide+Chlorthalidone (Treatment Grup)	餘憲鬱夢淵獵繭衊範壓(願襯壓選網艱願觸膚鏇) = 壓夢夢築遞遞鹹選衊壓夢鹹壓壓廠簾齋淵齋顧 (網鏇鑰顧糧襯選餘夢範, 製構憲窪衊範製鏇壓艱 ~ 構蓋廠糧餘製獵鑰襯鹹) 更多
ASN2019	N/A	结石 \| 高钙尿症	113	KCl	膚選衊壓網夢憲壓網餘(範繭積醖網鬱夢膚遞鑰) = 顧齋願鹽鏇選鑰夢願網顧膚衊齋選遞艱醖簾壓 (夢選網醖鑰網範觸夢觸, 0.2) 更多	积极	2019-11-05
				KCit	網簾鏇積積淵齋憲齋積(廠醖艱廠鹹選廠獵繭壓) = 願網範壓齋夢鏇網蓋艱襯網艱鏇醖簾夢淵醖選 (遞衊願膚簾鹹顧選齋膚, 0.3)